Urvay Semiha Elmaci, Yucel Birsen, Erdis Eda, Turan Nedim
Acıbadem Hospitals Group, Birsen Yücel, Kayseri, Turkey. Email:
Asian Pac J Cancer Prev. 2016 Oct 1;17(10):4693-4697. doi: 10.22034/apjcp.2016.17.10.4693.
Aim: The objective of this study is to investigate prognostic factors affecting survival of patients undergoing concurrent or sequential chemoradiotherapy (CRT) for stage III non-small-cell lung cancer (NSCL). Methods and materials: We retrospectively reviewed the clinical records of 148 patients with advanced, inoperable stage III NSCLC, who were treated between 2007 and 2015. Results: The median survival was found to be 19 months and 3-year overall survival was 27%. Age (<65 vs ≥65 years, p=0.026), stage (IIIA vs IIIB, p=0.033), dose of radiotherapy (RT) (<60 vs ≥60 Gy, p=0.024) and treatment method (sequential chemotherapy+RT vs concurrent CRT , p=0.023) were found to be factors affecting survival in univariate analyses. Gender, histological subtype, weight loss during CRT, performance status, induction/consolidation chemotherapy and presence of comorbidities did not affect survival (p>0.050). Conclusion: Young age, stage IIIA, radiotherapy dose and concurrent chemoradiotherapy may positively affect survival in stage III NSCL cases.
本研究的目的是调查影响Ⅲ期非小细胞肺癌（NSCL）患者接受同步或序贯放化疗（CRT）后生存的预后因素。方法和材料：我们回顾性分析了2007年至2015年间接受治疗的148例晚期、无法手术的Ⅲ期NSCLC患者的临床记录。结果：中位生存期为19个月，3年总生存率为27%。单因素分析发现，年龄（<65岁与≥65岁，p=0.026）、分期（IIIA期与IIIB期，p=0.033）、放疗剂量（<60 Gy与≥60 Gy，p=0.024）和治疗方法（序贯化疗+放疗与同步CRT，p=0.023）是影响生存的因素。性别、组织学亚型、CRT期间体重减轻、体能状态、诱导/巩固化疗和合并症的存在不影响生存（p>0.050）。结论：年轻、IIIA期、放疗剂量和同步放化疗可能对Ⅲ期NSCL病例的生存产生积极影响。
